Neurocrine names Eiry Roberts chief medical officer, replacing Sanjay Keswani

Neurocrine Biosciences disclosed in a Form 8-K that its Board of Directors appointed Eiry W. Roberts, M.D., as the company's new Chief Medical Officer, effective September 28, 2026, taking over the role from Sanjay Keswani, M.D.¹ The transition followed an earlier agreement: on September 25, 2026, Dr. Keswani and the Board mutually agreed that his service as Chief Medical Officer would end that same day.¹

Under the terms disclosed, Dr. Keswani will receive severance benefits under Section 4.1 of the company's Executive Severance Plan, which took effect February 7, 2025 and was filed as an exhibit to the 2024 Form 10-K.¹

For Dr. Roberts, the company said it will enter into an Amended and Restated Employment Agreement effective as of the transition date, updating an employment agreement originally signed with her on May 30, 2025 and previously amended on November 21, 2025.¹ Under that agreement, she will earn an annual base salary of $825,000 and will be eligible for a target cash bonus equal to 60% of her 2026 base pay.¹

Her equity package includes stock options worth about $625,000 vesting monthly over four years, restricted stock units worth about $250,000 vesting annually over four years, and performance-based restricted stock units worth about $375,000 tied to the same performance terms granted to other executive officers in February 2026.¹ The company said these equity grants will be issued two business days after Neurocrine files its next quarterly report on Form 10-Q, provided Dr. Roberts is still employed at that time.¹

Neurocrine noted that Dr. Roberts' existing equity awards will remain outstanding and continue vesting under their original terms during her employment.¹ The company said it plans to file the full Employment Agreement with its Form 10-Q for the quarter ending September 30, 2026.¹